CS23546, a highly potent small-molecule PD-L1 inhibitor with global patent protection exclusively discovered by the company, relieves the immunosuppressive activity mediated by the PD-1/PD-L1 signaling pathway by binding to PD-L1 and inducing endocytosis.CS23546 has shown good oral absorption and metabolic characteristics of local enrichment in tumor tissues in preclinical studies; significant anti-tumor efficacy in different tumor xenograft models was shown in monotherapy, and significant synergistic anti-tumor activities were shown in combination with chemotherapy or other products owned by the company, such as Chidamide and Chiauranib. With a stable process and controllable quality, CS23546 is expected to bring differentiated advantages as a new-generation oral small-molecule immune checkpoint inhibitor in the clinical treatment of different malignant tumors and has application potential for other PD-L1 signal-mediated immune-related diseases.

Indications under development

• The phase 1 clinical trial of CS23546 is progressing smoothly and the enrollment of the 4th dose group had been completed by Dec. 20, 2024.

• The company will perform the overseas investigational of new drug (IND) applications for monotherapy and combination therapies of this molecule in due course.